Form 4: ArriVent BioPharma General Counsel Acquires Stock Options

James Paul Kastenmayer, General Counsel of ArriVent BioPharma, acquired stock options for 102,000 shares on February 3, 2025.

Summary

• On February 3, 2025, James Paul Kastenmayer, the General Counsel of ArriVent BioPharma, Inc., was granted stock options to purchase 102,000 shares of common stock at an exercise price of $27.56 per share.
• The options vest as to 25% on February 3, 2026, and the remaining 75% vests in 36 equal monthly installments thereafter, contingent upon Kastenmayer's continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, aligning management interests with shareholders.

Positives

• The acquisition of stock options by a key executive aligns their interests with those of the shareholders, potentially incentivizing them to work towards the company's success.

Risks

• The vesting of the options is contingent upon Kastenmayer's continued service, creating a potential risk if he were to leave the company before the options are fully vested.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule implies a commitment from the executive to remain with the company for at least three years to fully vest the options.

Industry Context

Stock option grants are a common form of executive compensation in the biopharmaceutical industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biopharmaceutical industry.
• The vesting schedule of 25% after one year followed by monthly installments is a typical vesting arrangement.
• The size of the grant (102,000 shares) would need to be compared to grants made to executives in similar roles at comparable companies to assess its relative value.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates